Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who have a type of blood cancer called AML (either newly diagnosed or developed from another condition) that is in complete remission at the time of transplant, or who have MDS/AML with a low level of abnormal cells in the bone marrow (5% or fewer)
• People currently in their first or second round of treatment for their condition
• People aged 60 or older, or people under 60 who have one or more other health conditions, making them suitable for a reduced-intensity treatment approach rather than a full-strength conditioning regimen
• People who have a matching stem cell donor, either a family member or an unrelated person
• People whose transplant will use stem cells collected from the blood (not bone marrow or cord blood)
• People with a general health and activity level rated as reasonably functional (ECOG score of 0, 1, or 2) (confirm with trial site)
• People who give their written agreement to take part
• People who have previously had a stem cell transplant
• People covered by the French social security system
• Women who meet specific pregnancy prevention requirements, including using recommended contraception and having a negative pregnancy test before starting the study drug, or who are post-menopausal, or who have had a surgical procedure that means they cannot become pregnant

Who may not be able to join:

• People with a specific subtype of leukaemia called pro-myelocytic leukaemia
• People whose health allows them to have a full-strength (myeloablative) conditioning regimen
• People whose donor is a half-matched family member, a partially matched unrelated donor, or whose transplant would use umbilical cord blood
• Women who are pregnant or breastfeeding, or anyone unwilling to use required contraception
• People who are HIV positive
• People with active Hepatitis B or C infection
• People whose heart pumping function is below 50% (confirm with trial site)
• People with significantly reduced lung function (a specific lung capacity measure below 40%) (confirm with trial site)
• People with an infection that is not currently under control
• People with a type of anaemia involving the breakdown of red blood cells that is not currently under control
• People whose kidneys are not filtering blood well enough (below a certain threshold on standard kidney function tests) (confirm with trial site)
• People with significantly elevated liver function markers in their blood (confirm with trial site)
• People who have or have had another cancer, unless it was a skin cancer, cervical cancer, or another solid cancer that was fully treated with no signs of disease for at least 2 years
• People whose personal, family, social, or geographic circumstances may make it difficult to follow the trial schedule and requirements
• People who have taken part in another interventional clinical trial in the past month, or who plan to take part in another interventional trial at the same time as this study

Important: Always verify eligibility with the trial site directly before applying.